CN114160105B - 一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 - Google Patents
一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN114160105B CN114160105B CN202111425478.5A CN202111425478A CN114160105B CN 114160105 B CN114160105 B CN 114160105B CN 202111425478 A CN202111425478 A CN 202111425478A CN 114160105 B CN114160105 B CN 114160105B
- Authority
- CN
- China
- Prior art keywords
- magnetic
- core
- solvent
- mof
- organic framework
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012621 metal-organic framework Substances 0.000 title claims abstract description 51
- 239000003463 adsorbent Substances 0.000 title claims abstract description 50
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000004327 boric acid Substances 0.000 title claims abstract description 36
- 239000011258 core-shell material Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000002077 nanosphere Substances 0.000 claims abstract description 52
- 239000002777 nucleoside Substances 0.000 claims abstract description 45
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 150000003833 nucleoside derivatives Chemical class 0.000 claims abstract description 34
- 239000013096 zirconium-based metal-organic framework Substances 0.000 claims abstract description 31
- 229920001690 polydopamine Polymers 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 18
- 229960003638 dopamine Drugs 0.000 claims abstract description 17
- 239000003446 ligand Substances 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 15
- 229910052751 metal Inorganic materials 0.000 claims abstract description 15
- 239000002184 metal Substances 0.000 claims abstract description 15
- HJCNSOVRAZFJLK-UHFFFAOYSA-N C1=CC(C(=O)O)=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 HJCNSOVRAZFJLK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 6
- 210000002700 urine Anatomy 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 31
- 238000006243 chemical reaction Methods 0.000 claims description 26
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 19
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 12
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 12
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 11
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims description 11
- 125000003835 nucleoside group Chemical group 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 9
- 229960005305 adenosine Drugs 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 8
- 230000002194 synthesizing effect Effects 0.000 claims description 8
- 239000011976 maleic acid Substances 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 6
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 6
- 229940045145 uridine Drugs 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000007885 magnetic separation Methods 0.000 claims description 5
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 5
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 5
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229940029575 guanosine Drugs 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 10
- 229910052796 boron Inorganic materials 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000005619 boric acid group Chemical group 0.000 description 6
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001291 vacuum drying Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 230000006911 nucleation Effects 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000004729 solvothermal method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000002122 magnetic nanoparticle Substances 0.000 description 3
- 238000003760 magnetic stirring Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000004032 porphyrins Chemical class 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- -1 cyclic diester Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 239000013110 organic ligand Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- XWLVCCHVHXBFBC-SXBJJNBASA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O.C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XWLVCCHVHXBFBC-SXBJJNBASA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 229910007566 Zn-MOF Inorganic materials 0.000 description 1
- 229910007926 ZrCl Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015706 neuroendocrine disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 239000013094 zinc-based metal-organic framework Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/262—Synthetic macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/223—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material containing metals, e.g. organo-metallic compounds, coordination complexes
- B01J20/226—Coordination polymers, e.g. metal-organic frameworks [MOF], zeolitic imidazolate frameworks [ZIF]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
- B01J20/28009—Magnetic properties
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/48—Sorbents characterised by the starting material used for their preparation
- B01J2220/4806—Sorbents characterised by the starting material used for their preparation the starting material being of inorganic character
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/40—Aspects relating to the composition of sorbent or filter aid materials
- B01J2220/48—Sorbents characterised by the starting material used for their preparation
- B01J2220/4812—Sorbents characterised by the starting material used for their preparation the starting material being of organic character
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
本发明涉及一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用,包括以下步骤:将Fe3O4磁纳米球加入到弱碱性多巴胺的Tris‑水溶液中,自聚合反应得到聚多巴胺功能化的磁纳米球Fe3O4@PD;采用间‑四(4‑羧基苯基)卟啉和1,4‑对苯二硼酸为双配体,以Fe3O4@PD为核,加入金属源和溶剂,制备核壳结构硼酸掺杂的金属有机骨架磁性吸附剂Fe3O4@PD@BA‑Zr‑MOF。本发明制备的Fe3O4@PD@BA‑Zr‑MOF具有明显的核‑壳结构、大小均一、比表面积大,对核苷富集具有更好的选择性,富集容量高。
Description
技术领域
本发明属于分析技术领域,具体涉及一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用。
背景技术
含顺式二醇结构的生物分子如糖蛋白、碳水化合物、神经递质和核苷等具有重要的生理功能和药理活性。这些生物分子通常作为癌症、糖尿病、神经内分泌紊乱和心血管疾病的生物标志物。例如,尿液中的核苷被认为是潜在的癌症生物标志物,包括乳腺癌、肺癌和子宫颈癌等。由于这些生物分子的样品基质复杂且含量低,在直接仪器分析前,适当的样品预处理是去除干扰物和选择性富集含顺式二醇生物分子的关键步骤。
硼亲和法是利用硼酸配基和糖链之间可逆的共价反应来实现对糖蛋白/糖肽的富集。在碱性条件中,硼酸分子可与带有1,2位或者1,3位顺式二羟基结构的糖链发生羟基化反应生成环状二酯;当调节溶液pH为酸性后,环状二酯水解释放出结合的糖链和硼酸分子,通过调节pH开关作用从而实现对含顺式二醇分子的高选择性富集。目前已报道有各种硼亲和材料,如硼酸功能化的磁性纳米颗粒、整体柱、多孔有机聚合物、硅胶等,但是这些硼亲和材料的制备过程通常较为复杂、硼酸官能团接枝密度较低且通常伴有非特异性吸附,因此开发新型的硼亲和材料用于高选择性高效富集顺式二醇分子具有重要意义。
金属有机骨架(MOF)是一种由无机金属离子(或金属离子簇)和有机配体链段配位自组装形成的新型多孔晶体材料。金属的次级结构单元和有机配体的多样性使得MOF材料具有超强的可设计性。基于MOF较大的比表面积和亲和性质,在生物分离分析领域应用较为广泛。Bie等人利用MOF上的Au纳米粒子接枝硼酸官能团制得硼亲和MOF材料用于顺式二醇分子的富集分析(Z.Bie,et al.Analytica Chimica Acta 2019,1065,40-48)。Pan等制备了Zn-MOF,碳化得到层状碳材料,再利用缩合反应进一步修饰上硼酸官能团用于四种核苷的富集分离分析(Y.Pan,et al.New Journal of Chemistry 2018,42,2288-2294)。这些硼亲和材料制备过程复杂、富集操作繁琐、通常伴有非特异性吸附,因此设计制备亲水性的硼亲和磁性材料,减少非特异性吸附,高效高选择性富集分离分析顺式二醇分子非常必要。
发明内容
本发明的目的是克服现有技术中存在的问题,提供一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用,该吸附剂能够高效、高选择性、高容量富集核苷。
为实现上述目的,本发明磁性吸附剂的制备方法可采用下述技术方案:
包括以下步骤:
(1)取Fe3O4磁纳米球;
(2)将Fe3O4磁纳米球加入到弱碱性多巴胺的Tris-水溶液中,自聚合反应得到聚多巴胺功能化的磁纳米球Fe3O4@PD;
(3)采用间-四(4-羧基苯基)卟啉和1,4-对苯二硼酸为双配体,以Fe3O4@PD为核,加入金属源和溶剂,制备核壳结构硼酸掺杂的金属有机骨架磁性吸附剂Fe3O4@PD@BA-Zr-MOF。
进一步地,步骤(1)采用水热法合成Fe3O4磁纳米球;具体步骤包括:取FeCl3·6H2O和稳定剂加入溶剂中,得到混合液,调节混合液pH值为碱性,再在180~200℃下水热反应5~20h,洗涤分离得到Fe3O4磁纳米球;其中FeCl3·6H2O和稳定剂的质量比为(0.27~1.08):(0.1~0.5)。
更进一步地,步骤(1)的溶剂包括乙二醇和二乙二醇中至少一种,每20mL溶剂中添加0.27~1.08g的FeCl3·6H2O;稳定剂包括聚(4-苯乙烯磺酸-共聚-马来酸)钠盐;采用无水乙酸钠调节混合液pH值,且FeCl3·6H2O和无水乙酸钠的质量比为(0.27~1.08):1.5。
进一步地,步骤(2)中多巴胺的Tris-水溶液的pH值为8~10,浓度为1~5mg/mL;每120mL多巴胺的Tris-水溶液中加入60~240mg的Fe3O4磁纳米球;步骤(2)中自聚合反应是在常温下机械搅拌过夜;分离采用磁性分离。
进一步地,步骤(3)中采用Zr4+为金属源;溶剂采用DMF;金属源、间-四(4-羧基苯基)卟啉、4-对苯二硼酸、溶剂和Fe3O4@PD之间的比例为(25~75)mg:(8~12)mg:(5~8)mg:(4~20)mL:(50~300)mg。
进一步地,步骤(3)中是在120~130℃下反应48~72h。
如上所述制备方法制得的高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂。
如上所述高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂应用于高选择性富集分离尿液中的核苷分子,其技术方案是:取Fe3O4@PD@BA-Zr-MOF分散于碱性尿液样品中,使核苷分子完全吸附到Fe3O4@PD@BA-Zr-MOF上。
进一步地,所述的核苷分子为胞苷,尿苷,鸟苷和腺苷;Fe3O4@PD@BA-Zr-MOF的添加量为每2mL的尿液样品添加2~20mg;尿液样品的pH值为7~9。
如上所述高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂应用于核苷分子检测,其技术方案是:取Fe3O4@PD@BA-Zr-MOF分散于碱性尿液样品中,使核苷分子完全吸附到Fe3O4@PD@BA-Zr-MOF上,分离后洗脱核苷分子,将洗脱液过滤后进行色谱分析;
洗脱核苷分子采用质量分数为0.5%~3%三氟乙酸,洗脱时间为1~10min;
色谱分析条件为:选用C18液相色谱柱,其规格为25cm长,内径为4.6mm,填料粒径为5μm;所述流动相:A为25mmol磷酸二氢钠和B为乙腈,流速为1mL/min,柱温为25~30℃,检测器为紫外检测器,测定波长为245~265nm,进样量为5~20μL。
本发明相对于现有技术具有如下优点和效果:
1.本发明采用聚多巴胺作为分子连接剂,它均匀的包裹磁纳米颗粒,聚多巴胺表面的功能基团诱导和促进了金属有机骨架晶体的成核与生长,使硼酸掺杂的MOF均匀的生长在磁纳米球表面,制备的Fe3O4@PD@BA-Zr-MOF具有明显的核-壳结构、大小均一、比表面积大。
2.本发明采用双配体策略,通过一步溶剂热反应将硼酸官能团嫁接于MOF骨架内,此外卟啉配体的富氮骨架提供了一定的亲水作用,可减少一些非特异性吸附,其四个吡咯环形成“井”的结构使其更容易捕获核苷,因此所制备的Fe3O4@PD@BA-Zr-MOF对核苷富集具有更好的选择性,富集容量高。
3.本发明提供的基于Fe3O4@PD@BA-Zr-MOF的磁性选择性富集的操作步骤简单、萃取时间短、无有机溶剂消耗、对环境污染小,适用于含有顺式二醇结构的生物分子的富集分离分析。
附图说明
图1为核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂(Fe3O4@PD@BA-Zr-MOF)的制备示意图。
图2为实施例1中制得Fe3O4(A)、Fe3O4@PD(B)和Fe3O4@PD@BA-Zr-MOF(C and D不同放大倍数)的透射电镜图。
图3为实施例1中制得Fe3O4、Fe3O4@PD和Fe3O4@PD@BA-Zr-MOF的磁滞回线图。
图4不同pH溶液在对核苷分子选择性萃取效率的影响。
图5为Fe3O4@PD@BA-Zr-MOF磁性吸附剂对腺苷和脱氧腺苷的萃取前(a)和萃取后(b)萃取选择性对比色谱图。腺苷和2’-脱氧腺苷的浓度比分别为(A)1:1、(B)1:10和(C)1:100。
图6为尿样和加标尿样经Fe3O4@PD@BA-Zr-MOF磁性吸附剂萃取后的的色谱图,其中,(a)为尿样,(b)为加标0.5μg/mL核苷的尿样。
具体实施方式
下面结合附图和具体实施方式对本发明做进一步说明。
参见图1,本发明高选择性的核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂的制备方法:首先采用水热法合成分散性能好的Fe3O4磁纳米球,将制备的磁纳米球加入到弱碱性多巴胺的Tris-水溶液中,自聚合反应过夜得到聚多巴胺功能化的磁纳米球(Fe3O4@PD),采用Zr4+为金属源,间-四(4-羧基苯基)卟啉和1,4-对苯二硼酸为双配体,以Fe3O4@PD为核,制备核壳-结构的硼酸掺杂的金属有机骨架磁性吸附剂(Fe3O4@PD@BA-Zr-MOF)。
具体包括以下步骤:
(1)水热法合成Fe3O4纳米球
以0.27~1.08g FeCl3·6H2O为原料,乙二醇或其与二乙二醇以任意比例混合为溶剂,0.1~0.5g聚(4-苯乙烯磺酸-共聚-马来酸)钠盐(PSSMA,摩尔比3:1)为稳定剂,加入1.5g无水乙酸钠,180~200℃下反应5~20h,洗涤,磁性分离得到棕色Fe3O4磁纳米球。
(2)聚多巴胺的修饰
配制120mL浓度为1~5mg/mL的pH8~10的多巴胺Tris-水溶液,加入60~240mg步骤(1)制备的Fe3O4纳米球,常温下机械搅拌过夜,洗涤,磁性分离得到聚多巴胺修饰的磁纳米球(Fe3O4@PD)。
(3)硼酸掺杂的金属有机骨架的成核和生长
采用双配体策略合成硼酸掺杂的金属有机骨架,以25~75mg的ZrCl4为金属源,8~12mg的间-四(4-羧基苯基)卟啉和5~8mg的1,4-对苯二硼酸为双配体,4~20mL的DMF为溶剂,50~300mg Fe3O4@PD为核,混合均匀,120~130℃下反应48~72h,制备核壳结构的硼酸掺杂的金属有机骨架磁性吸附剂(Fe3O4@PD@BA-Zr-MOF),聚多巴胺表面的活性基团(羟基和氨基)促进了金属有机骨架晶体的成核与生长。
第二方面,提供一种利用上述的核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂应用于高选择性富集分离尿液中的核苷分子,其步骤为:取一定量的Fe3O4@PD@BA-Zr-MOF分散于碱性尿液样品中,涡旋震荡萃取1~50min,使核苷分子完全吸附到磁纳米球上,磁性分离,酸水洗脱核苷分子,将洗脱液过滤后进入高效液相色谱分析。
上述方法中,所述尿样处理步骤包括:
尿样取自实验室健康成员,使用前置于-20℃下保存。尿样室温解冻后,用NH4HCO3-NH3缓冲液按4:1比例稀释,调pH至7~9后,添加至5mL离心管中,然后用离心机在12000g下离心10min,上清液用作提取程序的样品。加标核苷尿样的预处理同上。
所述核苷为胞苷,尿苷,鸟苷,腺苷。
核壳结构磁性吸附剂的添加量为每2mL的尿液样品添加2~20mg。
所述的洗脱水溶液为0.5%~3%三氟乙酸(TFA),洗脱时间为1~10min。
本发明采用HPLC分析检测核苷分子,色谱条件为:
选用C18液相色谱柱,其规格为25cm长,内径为4.6mm,填料粒径为5μm;所述流动相:A为25mmol磷酸二氢钠溶液和B为乙腈,其中A:B=90:10(v/v),流速为1mL/min,柱温为25~30℃,检测器为紫外检测器,测定波长为245~265nm,进样量为5~20μL。
本发明通过采用多巴胺进行修饰,金属源为Zr4+,特定的双配体等条件协同配合,通过采用无水乙酸钠提供碱性环境;为了确保产物晶型,硼酸掺杂的金属有机骨架的成核和生长过程中采用DMF作为溶剂,各条件协同配合下,形成核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂,作为高选择性硼亲和材料。
本发明采用双配体策略将硼酸功能单体引入MOF骨架中制备了核-壳结构的磁性吸附剂;基于卟啉分子中的富氮骨架的亲水作用和MOF中丰富的硼酸基提供的硼亲和作用,该核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂对核苷具有较好的富集性能,富集选择性好,非特异性吸附小,富集容量高。
下面通过具体的实施例对本发明所制得的核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其用于尿液中核苷的选择性富集分离分析的过程进行详细阐述。
实施例1
本实施例提供了一种核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂的制备方法,包括以下步骤:
第一步:先采用水热法合成Fe3O4磁纳米球:称取0.5g聚(4-苯乙烯磺酸-共聚-马来酸)钠盐(PSSMA,摩尔比3:1)磁力搅拌下溶解于20mL乙二醇中,再加入0.54g FeCl3·6H2O溶解得到橘黄色澄清溶液,随后再加入1.5g无水乙酸钠,搅拌均匀后将上述溶液转移至反应釜里,放入烘箱200℃下反应10h,反应完成后,冷却至室温,用磁铁收集磁纳米球,用水和乙醇洗涤数次,真空干燥得到棕色Fe3O4磁纳米球。
第二步:采用聚多巴胺修饰磁纳米球:配制120mL浓度为2mg/mL的pH8.5的多巴胺Tris-水溶液,加入步骤第一步制备的Fe3O4磁纳米球200mg,常温下机械搅拌过夜。然后用水和乙醇清洗数次,磁性分离,再真空干燥,得到聚多巴胺修饰的磁纳米球(Fe3O4@PD)。
第三步:采用双配体策略,溶剂热法将MOF修饰于Fe3O4@PD表面:称取25mg氯化锆,10mg间-四(4-羧基苯基)卟啉和6.3mg 1,4-对苯二硼酸,加入4mL DMF,溶解完全后,加入聚多巴胺修饰的磁纳米球,超声数分钟混合均匀,倒入反应釜,放入烘箱120℃下反应48h,反应完成后,冷却至室温,磁性分离产物,用DMF和丙酮分别洗涤数次,真空干燥得到Fe3O4@PD@BA-Zr-MOF磁性吸附剂。
对各步骤制得的产物分别进行电镜扫描和磁响应测试,结果如图2和图3所示。
从图2中可以看出,Fe3O4粒径范围250~400nm之间,聚多巴胺层厚度为40~50nm,MOF材料厚度为25~35nm。此外,所制备的磁性吸附剂在水溶液中分散性能较好。
从图3中可以看出,Fe3O4、Fe3O4@PD和Fe3O4@PD@BA-Zr-MOF的饱和磁化值分别为62.0emu g-1,36.9emu g-1和24.4emu g-1,表明经修饰后的磁纳米材料仍具有良好的磁响应,可以用于磁性固相萃取,如将所得磁性吸附剂用于尿液中核苷的富集分离分析。
实施例2
本实施例提供了一种核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂的制备方法,包括以下步骤:
第一步:先采用水热法合成Fe3O4磁纳米球:称取0.1g聚(4-苯乙烯磺酸-共聚-马来酸)钠盐(PSSMA,摩尔比3:1)磁力搅拌下溶解于20mL二乙二醇中,再加入0.27g FeCl3·6H2O溶解得到橘黄色澄清溶液,随后再加入1.5g无水乙酸钠,搅拌均匀后将上述溶液转移至反应釜里,放入烘箱180℃下反应20h,反应完成后,冷却至室温,用磁铁收集磁纳米球,用水和乙醇洗涤数次,真空干燥得到棕色Fe3O4磁纳米球。
第二步:采用聚多巴胺修饰磁纳米球:配制120mL浓度为1mg/mL的pH8的多巴胺Tris-水溶液,加入步骤第一步制备的Fe3O4磁纳米球60mg,常温下机械搅拌过夜。然后用水和乙醇清洗数次,磁性分离,再真空干燥,得到聚多巴胺修饰的磁纳米球(Fe3O4@PD)。
第三步:采用双配体策略,溶剂热法将MOF修饰于Fe3O4@PD表面:称取50mg氯化锆,8mg间-四(4-羧基苯基)卟啉和5mg 1,4-对苯二硼酸,加入10mL DMF,溶解完全后,加入聚多巴胺修饰的磁纳米球,超声数分钟混合均匀,倒入反应釜,放入烘箱125℃下反应72h,反应完成后,冷却至室温,磁性分离产物,用DMF和丙酮分别洗涤数次,真空干燥得到Fe3O4@PD@BA-Zr-MOF磁性吸附剂。
实施例3
本实施例提供了一种核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂的制备方法,包括以下步骤:
第一步:先采用水热法合成Fe3O4磁纳米球:称取0.3g聚(4-苯乙烯磺酸-共聚-马来酸)钠盐(PSSMA,摩尔比3:1)磁力搅拌下溶解于20mL由乙二醇和二乙二醇构成的混合溶剂中,再加入1.08g FeCl3·6H2O溶解得到橘黄色澄清溶液,随后再加入1.5g无水乙酸钠,搅拌均匀后将上述溶液转移至反应釜里,放入烘箱190℃下反应5h,反应完成后,冷却至室温,用磁铁收集磁纳米球,用水和乙醇洗涤数次,真空干燥得到棕色Fe3O4磁纳米球。
第二步:采用聚多巴胺修饰磁纳米球:配制120mL浓度为5mg/mL的pH10的多巴胺Tris-水溶液,加入步骤第一步制备的Fe3O4磁纳米球240mg,常温下机械搅拌过夜。然后用水和乙醇清洗数次,磁性分离,再真空干燥,得到聚多巴胺修饰的磁纳米球(Fe3O4@PD)。
第三步:采用双配体策略,溶剂热法将MOF修饰于Fe3O4@PD表面:称取75mg氯化锆,12mg间-四(4-羧基苯基)卟啉和8mg 1,4-对苯二硼酸,加入20mL DMF,溶解完全后,加入聚多巴胺修饰的磁纳米球,超声数分钟混合均匀,倒入反应釜,放入烘箱130℃下反应60h,反应完成后,冷却至室温,磁性分离产物,用DMF和丙酮分别洗涤数次,真空干燥得到Fe3O4@PD@BA-Zr-MOF磁性吸附剂。
应用例1
本实施例提供了一种利用实施实例1所述的Fe3O4@PD@BA-Zr-MOF磁性吸附剂选择性萃取核苷分子的方法,包括以下步骤:
第一步 磁性固相萃取:取10mg磁性吸附剂,加入1mg/L核苷(包含胞苷、尿苷、鸟苷、腺苷)溶液2mL,振荡10min,磁性分离,倾倒出上清液后加入400μL 1%三氟乙酸洗脱5min,收集洗脱液,过滤后直接进入液相色谱分析。
第二步 液相色谱分析:选用C18液相色谱柱,其规格为25cm长,内径为4.6mm,填料粒径为5μm;所述流动相:A为25mmol磷酸二氢钠溶液和B为乙腈,其中A:B=98:2(v/v),流速为1mL/min,柱温为25℃,检测器为紫外检测器,测定波长为259nm,进样量为10μL。
应用例2
考察不同pH溶液在对核苷分子选择性萃取效率的影响。
按照实施实例2所述的方法萃取核苷分子,区别在于,调节核苷溶液的pH值,分别为7、7.5、8、8.5、9。由图4可知,随着核苷溶液的pH值增大,对胞苷(cytidine)和尿苷(uridine)的萃取富集性能逐渐增大,对鸟苷(guanosine)和腺苷(adenosine)的萃取性能先增大后降低,因此本发明选择pH为7~9的核苷溶液,优选8.5~9。
应用例3
考察干扰物与待测物的浓度比分别为1:1、10:1、100:1时,该磁性吸附剂对待测物的萃取选择性,材料处理及测试步骤和条件同实施例2,测试结果如图5所示。
从图5中可看出,该磁性吸附剂选择性地吸附腺苷并排除2’-脱氧腺苷,表明所制备的材料具有较好的富集选择性。
应用例4
本实施例提供一种利用上述磁性吸附剂高选择性富集尿液中核苷分子和HPLC分析方法。
包括以下步骤:
第一步 尿液预处理:尿样取自实验室健康成员,尿样取自实验室健康成员,使用前置于-20℃下保存。尿样室温解冻后,用NH4HCO3-NH3缓冲液按4:1比例稀释,调pH至9后,添加至5mL离心管中,然后用离心机在12000g下离心10min,上清液用作提取程序的样品。加标核苷尿样的预处理同上。
第二步 选择性富集:取2mL处理后的尿液或加标后的尿液于小瓶中,加入15mg磁性吸附剂,涡旋震荡10min后,经磁性分离弃去上清液,用缓冲液清洗磁性吸附剂两次后,再用400μL 1%TFA酸水溶液涡旋震荡洗脱5min,洗脱液经0.22μm滤膜过滤后直接进入HPLC分析。
第三步 液相色谱分析:选用C18液相色谱柱,其规格为25cm长,内径为4.6mm,填料粒径为5μm;所述流动相:A为25mmol磷酸二氢钠溶液和B为乙腈,其中A:B=98:2(v/v),流速为1mL/min,柱温为25℃,检测器为紫外检测器,测定波长为259nm,进样量为10μL。
分析结果如图6所示,从图6中可以看出该磁性吸附剂可以在加标的实际尿液中选择性富集核苷,表明该材料可以用于实际样品分析。
本发明公开了一种高选择性的核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂的制备及其对尿液中核苷选择性富集方面的应用。该方法首先采用水热法合成分散性能好的Fe3O4磁纳米球,多巴胺在弱碱性条件下自发聚合形成聚多巴胺包裹于磁纳米球表面,采用Zr4+为金属源,间-四(4-羧基苯基)卟啉和1,4-对苯二硼酸为双配体合成硼酸掺杂的金属有机骨架材料,聚多巴胺表面的活性基团(羟基和氨基)促进了金属有机骨架晶体的成核与生长。基于卟啉分子中的富氮骨架的亲水作用和金属有机骨架中丰富的硼酸基提供的硼亲和作用,该核-壳结构硼酸掺杂的金属有机骨架磁性吸附剂对核苷富集选择性好,且富集容量高。本发明提供的高选择性磁性吸附剂的制备方法简单,磁纳米颗粒大小均一,核壳结构形貌较好,对顺式二醇结构的分子的高选择性富集和分离具有较好的应用前景。
Claims (9)
1.一种核壳结构硼酸掺杂的金属有机骨架磁性吸附剂在高选择性富集分离尿液中的核苷分子中的应用,其特征在于:所述金属有机骨架磁性吸附剂的制备方法,包括以下步骤:
(1)合成Fe3O4磁纳米球;
(2)将Fe3O4磁纳米球加入到弱碱性多巴胺的Tris-水溶液中,自聚合反应得到聚多巴胺功能化的磁纳米球Fe3O4@PD;
(3)采用间-四(4-羧基苯基)卟啉和1,4-对苯二硼酸为双配体,以Fe3O4@PD为核,加入金属源和溶剂,制备能够富集核苷的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂Fe3O4@PD@BA-Zr-MOF;
步骤(3)中采用Zr4+为金属源;溶剂采用DMF;金属源、间-四(4-羧基苯基)卟啉、4-对苯二硼酸、溶剂和Fe3O4@PD之间的比例为(25~75)mg:(8~12)mg:(5~8)mg:(4~20)mL:(50~300)mg;
步骤(3)中是在120~130 ℃下反应48~72 h;
所述应用包括如下步骤:取Fe3O4@PD@BA-Zr-MOF分散于碱性尿液样品中,使核苷分子完全吸附到Fe3O4@PD@BA-Zr-MOF上。
2.根据权利要求1所述的应用,其特征在于:步骤(1)采用水热法合成Fe3O4磁纳米球;具体步骤包括:取FeCl3•6H2O和稳定剂加入溶剂中,得到混合液,调节混合液pH值为碱性,再在180~200 ℃ 下水热反应5~20 h,洗涤分离得到Fe3O4磁纳米球;其中FeCl3•6H2O和稳定剂的质量比为(0.27~1.08 ) :(0.1~0.5)。
3.根据权利要求2所述的应用,其特征在于:步骤(1)的溶剂包括乙二醇和二乙二醇中至少一种,每20mL溶剂中添加0.27~1.08g的FeCl3•6H2O;稳定剂包括聚(4-苯乙烯磺酸-共聚-马来酸)钠盐;采用无水乙酸钠调节混合液pH值,且FeCl3•6H2O和无水乙酸钠的质量比为(0.27~1.08 ):1.5。
4.根据权利要求1所述的应用,其特征在于:步骤(2)中多巴胺的Tris-水溶液的pH值为8~10,浓度为1~5 mg/mL;每120mL多巴胺的Tris-水溶液中加入60~240 mg的Fe3O4磁纳米球;分离采用磁性分离。
5.根据权利要求1所述的应用,其特征在于:所述的核苷分子为胞苷,尿苷,鸟苷和腺苷;Fe3O4@PD@BA-Zr-MOF的添加量为每2mL的尿液样品添加2~20 mg;尿液样品的pH值为7~9。
6.一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂在核苷分子检测中的应用,其特征在于:所述金属有机骨架磁性吸附剂的制备方法,包括以下步骤:
(1)合成Fe3O4磁纳米球;
(2)将Fe3O4磁纳米球加入到弱碱性多巴胺的Tris-水溶液中,自聚合反应得到聚多巴胺功能化的磁纳米球Fe3O4@PD;
(3)采用间-四(4-羧基苯基)卟啉和1,4-对苯二硼酸为双配体,以Fe3O4@PD为核,加入金属源和溶剂,制备能够富集核苷的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂Fe3O4@PD@BA-Zr-MOF;
步骤(3)中采用Zr4+为金属源;溶剂采用DMF;金属源、间-四(4-羧基苯基)卟啉、4-对苯二硼酸、溶剂和Fe3O4@PD之间的比例为(25~75)mg:(8~12)mg:(5~8)mg:(4~20)mL:(50~300)mg;
步骤(3)中是在120~130 ℃下反应48~72 h;
所述应用包括如下步骤:取Fe3O4@PD@BA-Zr-MOF分散于碱性尿液样品中,使核苷分子完全吸附到Fe3O4@PD@BA-Zr-MOF上,分离后洗脱核苷分子,将洗脱液过滤后进行色谱分析;
洗脱核苷分子采用质量分数为0.5%~3%三氟乙酸,洗脱时间为1~10 min;
色谱分析条件为:选用C18液相色谱柱,其规格为25 cm长,内径为4.6 mm,填料粒径为5μm;流动相: A 为25 mmol磷酸二氢钠和B为乙腈,流速为1 mL/min,柱温为25~30 ℃,检测器为紫外检测器,测定波长为245~265 nm,进样量为5~20 μL。
7.根据权利要求6所述的应用,其特征在于:步骤(1)采用水热法合成Fe3O4磁纳米球;具体步骤包括:取FeCl3•6H2O和稳定剂加入溶剂中,得到混合液,调节混合液pH值为碱性,再在180~200 ℃ 下水热反应5~20 h,洗涤分离得到Fe3O4磁纳米球;其中FeCl3•6H2O和稳定剂的质量比为(0.27~1.08 ) :(0.1~0.5)。
8.根据权利要求7所述的应用,其特征在于:步骤(1)的溶剂包括乙二醇和二乙二醇中至少一种,每20mL溶剂中添加0.27~1.08g的FeCl3•6H2O;稳定剂包括聚(4-苯乙烯磺酸-共聚-马来酸)钠盐;采用无水乙酸钠调节混合液pH值,且FeCl3•6H2O和无水乙酸钠的质量比为(0.27~1.08 ):1.5。
9.根据权利要求6所述的应用,其特征在于:步骤(2)中多巴胺的Tris-水溶液的pH值为8~10,浓度为1~5 mg/mL;每120mL多巴胺的Tris-水溶液中加入60~240 mg的Fe3O4磁纳米球;分离采用磁性分离。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111425478.5A CN114160105B (zh) | 2021-11-26 | 2021-11-26 | 一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111425478.5A CN114160105B (zh) | 2021-11-26 | 2021-11-26 | 一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114160105A CN114160105A (zh) | 2022-03-11 |
CN114160105B true CN114160105B (zh) | 2024-04-30 |
Family
ID=80481214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111425478.5A Active CN114160105B (zh) | 2021-11-26 | 2021-11-26 | 一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114160105B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115155532B (zh) * | 2022-06-29 | 2024-04-26 | 武汉工程大学 | 多氟代卟啉共价有机骨架磁纳米球及其制备方法和应用 |
CN115508475B (zh) * | 2022-11-01 | 2024-08-16 | 未名环境分子诊断(广东)有限公司 | 一种污水中地芬诺酯含量检测方法 |
CN116425995B (zh) * | 2023-06-12 | 2023-10-20 | 吉林省卓材新研科技有限公司 | 一种金属有机框架材料及其配体和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106512965A (zh) * | 2016-11-28 | 2017-03-22 | 复旦大学 | 一种金属有机骨架纳米复合材料的合成方法及其应用 |
CN107413313A (zh) * | 2017-07-18 | 2017-12-01 | 武汉大学 | 一种基于共价有机骨架材料的磁性固相萃取剂及其制备方法和应用 |
CN113231032A (zh) * | 2020-11-05 | 2021-08-10 | 中国科学院青海盐湖研究所 | 一种MoS2QDs@Zr-MOF/Co掺杂Fe3O4硼同位素吸附剂及其制备方法 |
-
2021
- 2021-11-26 CN CN202111425478.5A patent/CN114160105B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106512965A (zh) * | 2016-11-28 | 2017-03-22 | 复旦大学 | 一种金属有机骨架纳米复合材料的合成方法及其应用 |
CN107413313A (zh) * | 2017-07-18 | 2017-12-01 | 武汉大学 | 一种基于共价有机骨架材料的磁性固相萃取剂及其制备方法和应用 |
CN113231032A (zh) * | 2020-11-05 | 2021-08-10 | 中国科学院青海盐湖研究所 | 一种MoS2QDs@Zr-MOF/Co掺杂Fe3O4硼同位素吸附剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Zirconium-based highly porous metal-organic framework (MOF-545) as an efficient adsorbent for vortex assisted-solid phase extraction of lead from cereal, beverage and water samples;Şerife Tokalıoğlu等;Food Chemistry;第237卷;第707-715页 * |
功能化磁性微球对顺式二羟基物质的分离富集性能;樊花;中国博士学位论文全文数据库 工程科技I辑(第06期);摘要,正文部分第5-25、103-131页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114160105A (zh) | 2022-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114160105B (zh) | 一种高选择性的核壳结构硼酸掺杂的金属有机骨架磁性吸附剂及其制备方法和应用 | |
Bazargan et al. | Metal–organic framework-based sorbents in analytical sample preparation | |
Gao et al. | Post-synthetic modification of phenylboronic acid-functionalized magnetic covalent organic frameworks for specific enrichment of N-linked glycopeptides | |
Feng et al. | In-situ growth of boronic acid-decorated metal-organic framework on Fe3O4 nanospheres for specific enrichment of cis-diol containing nucleosides | |
Wang et al. | Functional dual hydrophilic dendrimer‐modified metal‐organic framework for the selective enrichment of N‐glycopeptides | |
Wu et al. | Solid-phase extraction of aflatoxins using a nanosorbent consisting of a magnetized nanoporous carbon core coated with a molecularly imprinted polymer | |
CN110586052B (zh) | 一种磁性复合多孔网络吸附材料的制备与应用 | |
Zhang et al. | Boronic acid-decorated metal-organic frameworks modified via a mixed-ligand strategy for the selective enrichment of cis-diol containing nucleosides | |
CN112321839B (zh) | 一种双金属共价有机骨架材料及其制备方法、适体传感器 | |
Wang et al. | Analysis of tetracyclines from milk powder by molecularly imprinted solid‐phase dispersion based on a metal–organic framework followed by ultra high performance liquid chromatography with tandem mass spectrometry | |
Ali et al. | Flexible and hierarchical metal-organic framework composite as solid-phase media for facile affinity-tip fabrication to selectively enrich glycopeptides and phosphopeptides | |
CN111537577B (zh) | 一种金属-有机骨架石墨烯类似物及其制备方法、适体传感器及其制备方法 | |
CN113209947B (zh) | 一种苯硼酸功能化Ti3C2Tx磁性复合材料及其制备方法和应用 | |
CN108732273A (zh) | 一种用于分析食品和饮用水中痕量磺胺类抗生素的方法 | |
CN110841612A (zh) | 一种磁性NH2-MOFs纳米材料的制备及其应用 | |
Zhang et al. | Hydrophilic carboxyl supported immobilization of UiO-66 for novel bar sorptive extraction of non-steroidal anti-inflammatory drugs in food samples | |
Yu et al. | Insights into the structure-performance relationships of extraction materials in sample preparation for chromatography | |
Feng et al. | Boronic acid grafted metal-organic framework for selective enrichment of cis-diol-containing compounds | |
Wu et al. | A novel Wulff‐type boronate acid‐functionalized magnetic metal‐organic framework imprinted polymer for specific recognition of glycoproteins under physiological pH | |
CN110339816A (zh) | 一种锆基金属有机骨架材料的制备方法及其应用 | |
Ding et al. | Facile synthesis of layered mesoporous covalent organic polymers for highly selective enrichment of N-glycopeptides | |
CN110618224A (zh) | 一种[H2Nmim][NTf2]@UiO-66-Br纳米复合材料及其应用 | |
Wu et al. | Binding characteristics of homogeneous molecularly imprinted polymers for acyclovir using an (acceptor–donor–donor)—(donor–acceptor–acceptor) hydrogen-bond strategy, and analytical applications for serum samples | |
Gao et al. | Fabrication of boronate‐decorated polyhedral oligomeric silsesquioxanes grafted cotton fiber for the selective enrichment of nucleosides in urine | |
Li et al. | Polyethyleneimine-functionalized Fe 3 O 4/attapulgite particles for hydrophilic interaction-based magnetic dispersive solid-phase extraction of fluoroquinolones in chicken muscle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |